Abstract
Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.
| Original language | English |
|---|---|
| Pages (from-to) | 397-402 |
| Number of pages | 6 |
| Journal | Expert Review of Cardiovascular Therapy |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 4 2017 |
Fingerprint
Keywords
- Heparin
- postpartum period
- pregnancy
- thromboprophylaxis
- venous thromboembolism
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine
Cite this
The prevention and treatment of venous thromboembolism in pregnancy. / Villani, Michela; Ageno, Walter; Grandone, Elvira; Dentali, Francesco.
In: Expert Review of Cardiovascular Therapy, Vol. 15, No. 5, 04.05.2017, p. 397-402.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The prevention and treatment of venous thromboembolism in pregnancy
AU - Villani, Michela
AU - Ageno, Walter
AU - Grandone, Elvira
AU - Dentali, Francesco
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.
AB - Introduction: Venous thromboembolism (VTE) in pregnancy represents an important cause of maternal morbidity and mortality in developed countries, with an incidence of 0.5–2.2 per 1000 pregnancies. In addition to hemostatic changes occurring during normal pregnancy, several risk factors have been identified. Thus, a variety of clinical conditions as well as fetal and maternal risks linked to a possible anticoagulant therapy should be considered for the management of VTE during pregnancy. Unfortunately, there is a paucity of high-quality evidence from randomized trials in this field, and current recommendations are based on observational studies or evidence gathered from studies in the non-pregnant population. Areas covered: The purpose of this review is to summarize available evidence on the prevention and treatment of pregnancy-related VTE. Expert commentary: Although the optimal prophylactic and therapeutic dosage has not yet been established, low-molecular-weight heparin (LMWH) represents the most efficacious and safe anticoagulant during pregnancy. Thus, after an accurate risk stratification of women during pregnancy and puerperium, LMWH should be recommended to women at risk for VTE and to those ones suffering from an acute event.
KW - Heparin
KW - postpartum period
KW - pregnancy
KW - thromboprophylaxis
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85018921338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018921338&partnerID=8YFLogxK
U2 - 10.1080/14779072.2017.1319279
DO - 10.1080/14779072.2017.1319279
M3 - Review article
C2 - 28425765
AN - SCOPUS:85018921338
VL - 15
SP - 397
EP - 402
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
IS - 5
ER -